Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema

Takuya Oyakawa; Keita Miura; Nao Muraoka; Kei Iida; Ayano Fujita; Tateaki Naito; Toshiaki Takahashi

doi:10.1111/1759-7714.15509

Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema

Thorac Cancer. 2024 Dec 13. doi: 10.1111/1759-7714.15509. Online ahead of print.

Authors

Takuya Oyakawa¹, Keita Miura², Nao Muraoka¹, Kei Iida^{1

3}, Ayano Fujita¹, Tateaki Naito², Toshiaki Takahashi²

Affiliations

¹ Division of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.
² Division of Thoracic oncology, Shizuoka Cancer Center, Shizuoka, Japan.
³ Mishimatoukai Hospital, Shizuoka, Japan.

PMID: 39671301
DOI: 10.1111/1759-7714.15509

Abstract

The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal-epithelial transition factor (MET) inhibitor-induced edema remain unclear. In a patient with tepotinib-induced edema and an N-terminal pro-brain natriuretic peptide (NTproBNP) level ≥ 300 pg/mL, the addition of empagliflozin to loop diuretics reduced the edema. This suggests that empagliflozin may be a treatment option for MET inhibitor-induced edema.

Keywords: MET; SGLT2 inhibitor; cardio‐oncology; edema; lung cancer.

Publication types

Case Reports